List of Firdapse drug patents

Firdapse is owned by Catalyst Pharms.

Firdapse contains Amifampridine Phosphate.

Firdapse has a total of 6 drug patents out of which 0 drug patents have expired.

Firdapse was authorised for market use on 28 November, 2018.

Firdapse is available in tablet;oral dosage forms.

Firdapse can be used as method of treating lambert-eaton myasthenic syndrome with amifampridine.

Drug patent challenges can be filed against Firdapse from 2022-11-28.

The generics of Firdapse are possible to be released after 25 February, 2037.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11274332 CATALYST PHARMS Methods of administering 3,4-diaminopyridine
Jun, 2032

(9 years from now)

US11274331 CATALYST PHARMS Methods of administering 3,4-diaminopyridine
Jun, 2032

(9 years from now)

US11268128 CATALYST PHARMS Methods of administering 3,4-diaminopyridine
Jun, 2032

(9 years from now)

US11060128 CATALYST PHARMS Methods of administering 3,4-diaminopyridine
Jun, 2032

(9 years from now)

US10793893 CATALYST PHARMS Methods of administering 3,4-diaminopyridine
May, 2034

(11 years from now)

US10626088 CATALYST PHARMS Determining degradation of 3,4-diaminopyridine
Feb, 2037

(13 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Nov 28, 2023
Orphan Drug Exclusivity (ODE) Nov 28, 2025
New Patient Population (NPP) Sep 29, 2025

Drugs and Companies using AMIFAMPRIDINE PHOSPHATE ingredient

NCE-1 date: 2022-11-28

Market Authorisation Date: 28 November, 2018

Treatment: Method of treating lambert-eaton myasthenic syndrome with amifampridine

Dosage: TABLET;ORAL

More Information on Dosage

FIRDAPSE family patents

16

United States

1

Canada

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic